EVAX Financials | Income, Balance Sheet & Cash Flow
The financial statements for EVAX (EVAX) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| VERU Veru Inc. | $2.44 -1.21% |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $0.85 -2.75% |
| SABS SAB Biotherapeutics, Inc. | $3.85 -1.79% |
| V Visa Inc. | $317.02 +0.61% |
| E Eni S.p.A. | $52.25 -5.67% |
| MURA Mural Oncology plc | $2.04 +0.00% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| VERU Veru Inc. | $2.44 | -1.21% | 39.16 M | -2.02 | -1.21 | 0.00% | Buy | 61 |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $0.85 | -2.75% | 2.90 M | -0.16 | -5.48 | 0.00% | Buy | 781 |
| SABS SAB Biotherapeutics, Inc. | $3.85 | -1.79% | 36.80 M | -4.87 | -0.79 | 0.00% | Buy | 346 |
| V Visa Inc. | $317.02 | +0.61% | 611.23 B | 29.77 | 10.65 | 0.79% | Buy | 6.34 |
| E Eni S.p.A. | $52.25 | -5.67% | 77.04 B | 28.55 | 1.83 | 4.73% | Hold | 837 |
| MURA Mural Oncology plc | $2.04 | +0.00% | 35.38 M | -0.29 | -6.93 | 0.00% | Hold | 128 |
Frequently Asked Questions
What are EVAX's latest financial results?
Review EVAX's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has EVAX's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is EVAX's cash flow situation and liquidity?
Cash flow statements reveal how EVAX generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does EVAX's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether EVAX is outperforming or lagging within its sector.
Are EVAX's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether EVAX's profits are repeatable and supported by strong fundamentals.